EC Number | Inhibitors | Comment | Organism | Structure |
---|---|---|---|---|
2.1.2.9 | SB-734453 | - |
Staphylococcus aureus |
EC Number | Natural Substrates | Organism | Comment (Nat. Sub.) | Natural Products | Comment (Nat. Pro.) | Rev. | Reac. |
---|---|---|---|---|---|---|---|
2.1.2.9 | 10-formyltetrahydrofolate + L-methionyl-tRNAfMet | Staphylococcus aureus | - |
tetrahydrofolate + N-formylmethionyl-tRNAfMet | - |
? | |
2.1.2.9 | 10-formyltetrahydrofolate + L-methionyl-tRNAfMet | Staphylococcus aureus WCUH29 | - |
tetrahydrofolate + N-formylmethionyl-tRNAfMet | - |
? |
EC Number | Organism | UniProt | Comment | Textmining |
---|---|---|---|---|
2.1.2.9 | Staphylococcus aureus | - |
hospital-acquired methicillin-resistant strain | - |
2.1.2.9 | Staphylococcus aureus WCUH29 | - |
hospital-acquired methicillin-resistant strain | - |
EC Number | Substrates | Comment Substrates | Organism | Products | Comment (Products) | Rev. | Reac. |
---|---|---|---|---|---|---|---|
2.1.2.9 | 10-formyltetrahydrofolate + L-methionyl-tRNAfMet | - |
Staphylococcus aureus | tetrahydrofolate + N-formylmethionyl-tRNAfMet | - |
? | |
2.1.2.9 | 10-formyltetrahydrofolate + L-methionyl-tRNAfMet | - |
Staphylococcus aureus WCUH29 | tetrahydrofolate + N-formylmethionyl-tRNAfMet | - |
? |
EC Number | Synonyms | Comment | Organism |
---|---|---|---|
2.1.2.9 | FMT | - |
Staphylococcus aureus |
2.1.2.9 | formyl-methionyl transferase | - |
Staphylococcus aureus |
EC Number | Cofactor | Comment | Organism | Structure |
---|---|---|---|---|
2.1.2.9 | 10-formyltetrahydrofolate | - |
Staphylococcus aureus |
EC Number | General Information | Comment | Organism |
---|---|---|---|
2.1.2.9 | malfunction | formyl-methionyl transferase mutants demonstrate reduced virulence factor production and pathogenicity. Loss-of-function mutations in the enzyme impart pleiotropic effects that include a reduced growth rate, a nonhemolytic phenotype, and a drastic reduction in production of multiple extracellular proteins, including key virulence factors, such as alpha-hemolysin and Panton-Valentine leukocidin, that have been associated with Staphylococcus aureus pathogenicity. Consequently, Staphylococcus aureus formyl-methionyl transferase mutants are greatly attenuated in neutropenic and nonneutropenic murine pyelonephritis infection models and show very high survival rates compared with wild-type Staphylococcus aureus. FMT-null mutants have a more severe fitness cost than previously anticipated, leading to a substantial loss of pathogenicity and a restricted ability to produce an invasive infection. Lack of transformylase affects the production of additional virulence factors, with reductions in total extracellular proteins of at least 50% observed in supernatants of cultures from the different Staphylococcus aureus WCUH29 FMT mutants | Staphylococcus aureus |
2.1.2.9 | physiological function | protein synthesis initiates with formyl-methionyl-tRNAi, and therefore, all newly synthesized polypeptides contain an N-formyl-methionine terminal end that, in most cases, is not retained in mature proteins | Staphylococcus aureus |